Literature DB >> 30508594

Ovarian cancer stem cells and their role in drug resistance.

Zalitha Pieterse1, Monica Angelica Amaya-Padilla1, Terence Singomat1, Mudra Binju1, Bau Dilam Madjid1, Yu Yu1, Pritinder Kaur2.   

Abstract

Ovarian cancer is typically diagnosed at advanced stages (III or IV), with metastasis ensuing at stage III. Complete remission is infrequent and is not achieved in almost half of the women diagnosed with ovarian cancer. Consequently, management and treatment of this disease is challenging as many patients are faced with tumour recurrence disseminating to surrounding organs further complicated with acquired chemo-resistance. The cancer stem cell theory proposes the idea that a drug resistant subset of tumour cells drive tumour progression, metastasis and ultimately, recurrent disease. In the ovarian cancer field, cancer stem cells remain elusive with significant gaps in our knowledge. The characteristics and specific role of ovarian cancer stem cells in recurrence still requires further research since different studies often arrive at contradictory conclusions. Here we present a review and critical analysis of current research conducted in the field of ovarian cancer stem cells and their potential role in drug resistance including several signalling pathways within these cells that affect the viability of targeted therapies.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Chemoresistance; Microenvironment; Ovarian cancer; Stem cell markers

Mesh:

Year:  2018        PMID: 30508594     DOI: 10.1016/j.biocel.2018.11.012

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  23 in total

1.  Expression of CD44+/CD24-, RAD6 and DDB2 on chemotherapy response in ovarian Cancer: A prospective flow cytometry study.

Authors:  Unedo Hence Markus Sihombing; Gatot Purwoto; Supriadi Gandamihardja; Alida R Harahap; Primariadewi Rustamadji; Aria Kekalih; Retno Widyawati; Dzicky Rifqi Fuady
Journal:  Gynecol Oncol Rep       Date:  2022-06-03

2.  Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.

Authors:  Qia Xu; Yun Liu; Shenyi Wang; Jing Wang; Liwei Liu; Yin Xu; Yide Qin
Journal:  BMC Cancer       Date:  2022-06-08       Impact factor: 4.638

3.  Identification of microRNA expression profiles of CD44+ ovarian cancer stem cells.

Authors:  Luyao Wang; Xiaogai Zhi; Yingying Lu; Yu Cong; Ziyi Fu; Jian Cao; Sujuan Xu; Juan Lv; Hongjie Ruan
Journal:  Arch Gynecol Obstet       Date:  2022-01-25       Impact factor: 2.493

Review 4.  Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model.

Authors:  Eric N Horst; Michael E Bregenzer; Pooja Mehta; Catherine S Snyder; Taylor Repetto; Yang Yang-Hartwich; Geeta Mehta
Journal:  Acta Biomater       Date:  2021-04-30       Impact factor: 10.633

Review 5.  Presence and role of stem cells in ovarian cancer.

Authors:  Natasa Kenda Suster; Irma Virant-Klun
Journal:  World J Stem Cells       Date:  2019-07-26       Impact factor: 5.326

6.  Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis.

Authors:  Kun Song; Jingduo Hao; Zuyin Ge; Pushi Chen
Journal:  J Oncol       Date:  2020-02-13       Impact factor: 4.375

Review 7.  MiR-135a biogenesis and regulation in malignancy: a new hope for cancer research and therapy.

Authors:  Zhe Cao; Jiangdong Qiu; Gang Yang; Yueze Liu; Wenhao Luo; Lei You; Lianfang Zheng; Taiping Zhang
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248

8.  Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-β pathway.

Authors:  Haiyan Wen; Min Qian; Jing He; Meihui Li; Qing Yu; Zhengwei Leng
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

Review 9.  Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells.

Authors:  Rhiane Moody; Kirsty Wilson; Anthony Jaworowski; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

10.  Chemokine CCL20 promotes the paclitaxel resistance of CD44+CD117+ cells via the Notch1 signaling pathway in ovarian cancer.

Authors:  Min Chen; Juan Su; Chunmei Feng; Ying Liu; Li Zhao; Yongjie Tian
Journal:  Mol Med Rep       Date:  2021-07-19       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.